Lyra Therapeutics (LYRA) Capital Expenditures (2019 - 2025)

Quarterly Capital Expenditures rose 265.52% to $96000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.4 million through Dec 2025, up 1.37% year-over-year, with the annual reading at $116000.0 for FY2025, 95.04% down from the prior year.

Lyra Therapeutics' Capital Expenditures history spans 7 years, with the latest figure at $96000.0 for Q4 2025.

  • Capital Expenditures came in at $96000.0 for Q4 2025, up from -$58000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $2.3 million in Q4 2021 to a low of -$736000.0 in Q3 2021.
  • The 5-year median for Capital Expenditures is $93000.0 (2022), against an average of $388588.2.
  • Year-over-year, Capital Expenditures surged 14400.0% in 2021 and then plummeted 502.82% in 2024.
  • Lyra Therapeutics' Capital Expenditures stood at $2.3 million in 2021, then plummeted by 98.8% to $28000.0 in 2022, then soared by 2096.43% to $615000.0 in 2023, then plummeted by 109.43% to -$58000.0 in 2024, then soared by 265.52% to $96000.0 in 2025.
  • Per Business Quant, the three most recent readings for LYRA's Capital Expenditures are $96000.0 (Q4 2025), -$58000.0 (Q4 2024), and $2.3 million (Q3 2024).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Capital Expenditures (Qtr)
1 Quantum Biopharma 1,384,976.65 Bn 1,384,976.64 Bn - -
2 Alterity Therapeutics 777,208.84 Bn 777,208.81 Bn - -
3 Legend Biotech 2,801.00 Bn 2,800.10 Bn 242.10 Mn -
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn - -
5 Akari Therapeutics 605.66 Bn 605.66 Bn - -
6 Vertex Pharmaceuticals 110.17 Bn 102.92 Bn 2.59 Bn 133.40 Mn
7 Regeneron Pharmaceuticals 66.86 Bn 58.11 Bn 3.31 Bn 230.60 Mn
8 Evaxion A 65.12 Bn 65.10 Bn - -
9 Alnylam Pharmaceuticals 39.94 Bn 36.94 Bn 959.66 Mn 21.83 Mn
10 Lyra Therapeutics - - - 96,000.00

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 96,000.00
Dec 31, 2025 96,000.00
Dec 31, 2024 -58,000.00
Dec 31, 2024 -58,000.00
Sep 30, 2024 2.33 Mn
Sep 30, 2024 2.33 Mn
Jun 30, 2024 -286,000.00
Jun 30, 2024 -286,000.00
Mar 31, 2024 350,000.00
Mar 31, 2024 350,000.00
Dec 31, 2023 615,000.00
Dec 31, 2023 615,000.00
Sep 30, 2023 -108,000.00
Sep 30, 2023 -108,000.00
Jun 30, 2023 71,000.00
Jun 30, 2023 71,000.00
Mar 31, 2023 45,000.00
Mar 31, 2023 45,000.00
Dec 31, 2022 28,000.00
Dec 31, 2022 28,000.00
Sep 30, 2022 130,000.00
Sep 30, 2022 130,000.00
Jun 30, 2022 -87,000.00
Jun 30, 2022 -87,000.00
Mar 31, 2022 93,000.00
Mar 31, 2022 93,000.00
Dec 31, 2021 2.34 Mn
Dec 31, 2021 2.34 Mn
Sep 30, 2021 -736,000.00
Sep 30, 2021 -736,000.00
Jun 30, 2021 625,000.00
Jun 30, 2021 625,000.00
Mar 31, 2021 1.16 Mn
Mar 31, 2021 1.16 Mn
Dec 31, 2020 -469,000.00
Dec 31, 2020 -469,000.00
Sep 30, 2020 644,000.00
Sep 30, 2020 644,000.00
Jun 30, 2020 22,000.00
Jun 30, 2020 22,000.00
Mar 31, 2020 8,000.00
Mar 31, 2020 8,000.00
Dec 31, 2019 -129,000.00
Dec 31, 2019 -129,000.00
Sep 30, 2019 10,000.00
Sep 30, 2019 10,000.00
Jun 30, 2019 69,000.00
Jun 30, 2019 69,000.00
Mar 31, 2019 52,000.00
Mar 31, 2019 52,000.00